Whereas in Japan, the drug was approved in 2005 for relapsed or refractory CD33-positive AML with the US’s original regimen of 9 mg/m2 for two doses at least 14 days apart has been applied, indicating risks underlying the prescription. This evidence concerns the gene CD33 and acute myeloid leukemia.